Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild to moderate SARS-CoV-2 in Qatar

  1. Ahmed Zaqout
  2. Muna A. Almaslamani
  3. Hiam Chemaitelly
  4. Samar A. Hashim
  5. Ajithkumar Ittaman
  6. Abeir Alimam
  7. Fatma Rustom
  8. Joanne Daghfal
  9. Mohammed Abukhattab
  10. Sawsan AlMukdad
  11. Anvar Hassan Kaleeckal
  12. Ali Nizar Latif
  13. Adeel A. Butt
  14. Roberto Bertollini
  15. Abdullatif Al-Khal
  16. Ali S. Omrani
  17. Laith J. Abu-Raddad
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Effectiveness of sotrovimab against severe, critical, or fatal COVID-19 was investigated in Qatar using a case-control study design at a time when BA.2 Omicron subvariant dominated incidence. Adjusted odds ratio of progression to severe, critical, or fatal COVID-19, comparing those sotrovimab-treated to those untreated, was 2.67-fold higher (95% CI: 0.60-11.91).

Related articles

Related articles are currently not available for this article.